The randomized Phase III SIERRA (Study of Iomab-B in Elderly relapsed or refractory AML) trial: Successful allogeneic hematopoietic stem cell transplantation using treatment with Iomab-B-led regimen for patients with active, relapsed or refractory AML with failed targeted therapies Meeting Abstract
| Authors: | Nath, R.; Seropian, S.; Choe, H.; Litzow, M. R.; Abboud, C.; Koshy, N.; Stiff, P. J.; Tomlinson, B.; Abhyankar, S.; Foran, J. M.; Hari, P.; Chen, G. L.; Al-Kadhimi, Z. S.; Kebriaei, P.; Sabloff, M.; Orozco, J. J.; Jamieson, K.; Magalhaes-Silverman, M.; Van Besien, K.; Schuster, M.; Law, A.; Abedin, S.; Larkin, K.; Rowley, S.; Munshi, P.; Cook, R.; Mayer, S.; Levy, M. Y.; Lazarus, H. M.; Sandmaier, B. M.; Reddy, V.; Spross, J.; McNamara, K.; Haeuber, E.; Vusirikala, M.; Nahar, A.; Pagel, J. M.; Giralt, S. A.; Desai, A.; Gyurkocza, B. |
| Abstract Title: | The randomized Phase III SIERRA (Study of Iomab-B in Elderly relapsed or refractory AML) trial: Successful allogeneic hematopoietic stem cell transplantation using treatment with Iomab-B-led regimen for patients with active, relapsed or refractory AML with failed targeted therapies |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | biomarkers; aml; tp53; acute myeloid leukemia; runx1; npm1 |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S309 |
| End Page: | S310 |
| Language: | English |
| ACCESSION: | WOS:001062479600212 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01076-5 |
| Notes: | Meeting Abstract: AML-521 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work